Market Overview

UPDATE: Bank of America Initiates Durata Therapeutics at Buy with $12 PO

What Investors Should Be Watching In The Antibiotic Space
Benzinga's Top Downgrades

Bank of America initiated coverage on Durata Therapeutics (NASDAQ: DRTX) with a Buy rating and a price objective of $12 a share on the potential that dalbavancin may represent a paradigm treatment change.

Bank of America noted, "Durata is a new public company developing dalbavancin, a long-acting antibiotic for treating gram positive infections including MRSA. Dosing for skin infections is two infusions, a week apart, which could be delivered in the ER or in an out-patient setting, potentially helping to avoid hospital stay for a portion of the 2mn admissions per year for serious skin infections. Valuation is attractive in our view, with potential upside from near-term phase 3 results, but we expect it could take many years to change the treatment paradigm."

Durata Therapeutics closed at $7.35 on Friday.

Latest Ratings for DRTX

Oct 2014Roth CapitalDowngradesBuyNeutral
Oct 2014Credit SuisseDowngradesOutperformNeutral
Oct 2014RBC CapitalDowngradesOutperformSector Perform

View More Analyst Ratings for DRTX
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Initiation Pre-Market Outlook Analyst Ratings


Related Articles (DRTX)

View Comments and Join the Discussion!